Welcome to our dedicated page for Accuray Incorp news (Ticker: ARAY), a resource for investors and traders seeking the latest updates and insights on Accuray Incorp stock.
Accuray Incorporated (NASDAQ: ARAY) pioneers precision radiation therapy systems that redefine cancer treatment standards. This dedicated news hub provides investors and healthcare professionals with timely updates on corporate developments, clinical advancements, and strategic initiatives shaping the future of radiation oncology.
Track all essential updates in one place, including earnings announcements, regulatory milestones, and technological breakthroughs related to flagship platforms like CyberKnife and Radixact. Our curated feed simplifies monitoring of partnership agreements, research collaborations, and market expansion efforts critical to understanding Accuray's position in medical technology.
Discover comprehensive coverage of operational updates, leadership changes, and product enhancements that impact clinical workflows and patient outcomes. The resource is designed to help stakeholders assess Accuray's progress in developing adaptive radiotherapy solutions with real-time tumor tracking capabilities.
Bookmark this page for streamlined access to verified information about ARAY, including innovation roadmaps and quality control certifications. Check regularly for objective reporting on developments influencing radiation oncology practices worldwide.
Accuray announced that Unicancer has selected three Radixact Systems equipped with ClearRT imaging and Synchrony technology for personalized cancer care. With over 30 Accuray systems in use, Unicancer aims to enhance treatment precision and efficiency. The new Radixact purchase complements their existing TomoTherapy platform and reflects Unicancer's commitment to delivering high-quality radiation therapy. Suzanne Winter, Accuray's president, expressed confidence in their technologies, while Unicancer highlighted the importance of advanced features in improving patient outcomes.
Accuray announced that Nagoya City University Hospital is the first facility in Japan to treat cancer patients using its Radixact® System equipped with ClearRT™ helical fan-beam kVCT imaging. This innovation enhances imaging clarity, allowing medical teams to make informed treatment decisions. The introduction of this system is particularly important, given that Japan recorded over one million new cancer cases in 2020. The Radixact System's advanced capabilities offer precise radiation targeting, minimizing damage to healthy tissue, thereby improving patient care.
Accuray Incorporated (NASDAQ: ARAY) announced that its CyberKnife robotic radiotherapy platform outperforms conventional linear accelerators in reducing late bladder toxicity in prostate cancer treatments, according to the PACE trial data. Presented at the European Society for Radiotherapy and Oncology congress, the study found that patients receiving CyberKnife SBRT experienced half the bladder side effects compared to traditional methods. The trial involved 874 patients, with significant findings indicating that fewer treatment sessions lead to increased patient satisfaction and lower out-of-pocket costs.
Accuray Incorporated (NASDAQ: ARAY) has appointed Mika Nishimura to its Board of Directors, effective August 17, 2021. Ms. Nishimura brings over 25 years of experience in the medical device industry and has held significant roles in product commercialization and strategic growth. Her previous positions include Vice President at nVision Medical Corporation and Auxogyn Incorporated. The addition of Nishimura aims to enhance Accuray's innovation and growth strategy in the radiation therapy sector, especially as the company seeks to expand its impact in oncology.
Accuray Incorporated (NASDAQ: ARAY) reported Q4 fiscal 2021 results with gross orders of $112.7 million, a 19% increase year-over-year. Net revenue reached $110.9 million, up 17%. Despite these gains, the company faced a net loss of $11.1 million due to a $9.9 million one-time refinancing charge. For the fiscal year, total revenue was $396.3 million, a 3.5% increase, with an ending backlog of $616.4 million. Looking ahead, Accuray forecasts fiscal year 2022 revenue between $410 million and $420 million.
Accuray (NASDAQ: ARAY) announced the first cancer treatment in Asia utilizing the Radixact® System with ClearRT™ imaging at Hong Kong Sanatorium & Hospital (HKSH). This advanced technology enhances imaging quality, enabling precise targeting of tumors while minimizing damage to healthy tissue. The initial case involved a 35-year-old patient with tongue cancer. ClearRT significantly reduced imaging and registration times by 77%, allowing for improved patient throughput and treatment accuracy. Accuray continues to emphasize innovation in cancer treatment solutions to enhance patient care.
Accuray Incorporated (NASDAQ: ARAY) announced it will report its financial results for Q4 and FY 2021, which ended on June 30, 2021, on August 11, 2021. The results will be shared after market close, with a conference call scheduled at 1:30 p.m. PT / 4:30 p.m. ET on the same day. Investors can access the call via dial-in numbers or through a live webcast available on the company's Investor Relations website. The replay of the call will be available for one week post-event.
Accuray announced the successful treatment of Mac, a Fox Terrier Mix, using the Radixact® System with Synchrony® technology for lung cancer. This treatment allowed for real-time tumor tracking during radiation therapy, ensuring minimal damage to healthy tissue. The procedure required only three hospital visits, emphasizing the efficiency and effectiveness of the new system. The clinical team at the University of Wisconsin-Madison, which has extensive experience with the TomoTherapy® platform, highlighted the potential for this system to expand treatment options for various cancers in pets.
Accuray (NASDAQ: ARAY) has announced the promotion of Suzanne Winter to president, effective July 1, 2021. With over 25 years in medical technology, Winter previously served as chief commercial officer. In her new role, she will oversee commercial operations, R&D, global manufacturing, service, and quality organizations. CEO Joshua Levine expressed confidence in Winter's leadership to drive revenue growth and manage day-to-day operations, allowing him to focus on strategic collaborations. Winter emphasized her commitment to innovation and improving patient outcomes.
Accuray Incorporated (NASDAQ: ARAY) launched RayStation treatment planning support for its CyberKnife M6 and S7 robotic systems, enhancing integration within radiation oncology departments. This system simplifies workflows, allowing clinicians to create treatment plans using various radiotherapy devices in one platform. Key features include advanced motion tracking, real-time dose adjustment, and a wide range of treatment angles. The update aims to improve operational efficiency and patient outcomes, solidifying Accuray's position in radiation oncology.
